Cargando…

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis

Mostrar otras versiones (1)

BACKGROUND: The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial. METHODS: Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández-Ruiz, Mario, López-Medrano, Francisco, Carretero, Octavio, Parra, Patricia, Ruiz-Merlo, Tamara, Aguado, José María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260823/ https://www.ncbi.nlm.nih.gov/pubmed/34243954 http://dx.doi.org/10.1016/j.medcli.2021.06.014

Ejemplares similares

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Discordance Between SARS-CoV-2–specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2021)

Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study
por: López-Medrano, Francisco, et al.
Publicado: (2021)

Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
por: San-Juan, Rafael, et al.
Publicado: (2022)

Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
por: Górgolas Hernández-Mora, Miguel, et al.
Publicado: (2021)

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Influence of single-nucleotide polymorphisms in TLR3 (rs3775291) and TLR9 (rs352139) on the risk of CMV infection in kidney transplant recipients
por: Redondo, Natalia, et al.
Publicado: (2022)

Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients
por: Tajuelo, Ana, et al.
Publicado: (2022)

Corrigendum: Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients
por: Tajuelo, Ana, et al.
Publicado: (2022)

Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation
por: Redondo, Natalia, et al.
Publicado: (2022)

Impact of polymorphisms in genes orchestrating innate immune responses on replication kinetics of Torque teno virus after kidney transplantation
por: Redondo, Natalia, et al.
Publicado: (2022)

Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection
por: de la Calle, Cristina, et al.
Publicado: (2021)

Long-Term Follow-Up of Patients Diagnosed with COVID-19-Associated Pulmonary Aspergillosis (CAPA)
por: Ruiz-Ruigómez, María, et al.
Publicado: (2022)

Tocilizumab in patients infected by SARS-CoV2()
por: Sancho, Milagros, et al.
Publicado: (2021)

[(18)F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab
por: Signore, Alberto, et al.
Publicado: (2022)

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
por: Morena, Valentina, et al.
Publicado: (2020)

Cytomegalovirus Exposure and the Risk of Overall Infection After Kidney Transplantation: A Cohort Study on the Indirect Effects Attributable to Viral Replication
por: Rodríguez-Goncer, Isabel, et al.
Publicado: (2022)

Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study
por: Dolci, Giovanni, et al.
Publicado: (2021)

Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis
por: Urbina, Tomas, et al.
Publicado: (2022)

COVID-19 in solid organ transplant recipients: A single-center case series from Spain
por: Fernández-Ruiz, Mario, et al.
Publicado: (2020)

69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER
por: Macatangay, M.V.R., et al.
Publicado: (2022)

Inhaled budesonide for early treatment of COVID-19
por: San-Juan, Rafael, et al.
Publicado: (2021)

Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events()
por: Rodríguez-Goncer, Isabel, et al.
Publicado: (2022)

Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France
por: Laffont-Lozes, Paul, et al.
Publicado: (2023)

Residual lesions on chest-Xray after SARS-CoV-2 pneumonia: Identification of risk factors()
por: Gómez Herrero, Helena, et al.
Publicado: (2022)

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma
por: Rusconi, Chiara, et al.
Publicado: (2020)

Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities
por: Serrano Fernández, Leyre, et al.
Publicado: (2022)

Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls
por: Mert, Ali, et al.
Publicado: (2021)

Lack of evidence for infectious SARS-CoV-2 in feces and sewage
por: Albert, Sandra, et al.
Publicado: (2021)

Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease()
por: González-Castro, A., et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Impact of lung ultrasound during the SARS-CoV-2 pandemic: Distinction between viral and bacterial pneumonia()
por: Tung-Chen, Yale, et al.
Publicado: (2022)

Effectiveness of Steroid Treatment for SARS-CoV-2 Pneumonia With Cryptogenic Organizing Pneumonia-Like Reaction: A Case Report
por: Kim, Taehwa, et al.
Publicado: (2020)

Incidence of Secondary Bacterial Infections Following Utilization of Tocilizumab for the Treatment of COVID-19 – A Matched Retrospective Cohort Study
por: Moore, Joanna L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8hh8t7beklh9f6l3j8rl7vc2n